Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 3 days ago
Treatment with hydroxychloroquine appears to significantly reduce viral load in patients with the novel coronavirus disease (COVID-19), with its beneficial effects reinforced by adding azithromycin, results of a recent study have shown.
Dr. Joseph Delano Fule Robles, 04 Sep 2017

A recent genome-wide association study (GWAS) performed by investigators from the Chinese University of Hong Kong (CUHK) has found potential new indications for existing drugs for the treatment of various psychiatric disorders. 

Audrey Abella, 27 Mar 2020
The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.

Once-weekly carfilzomib dosing preferable for relapsed/refractory multiple myeloma

16 Jan 2020

The once-weekly carfilzomib regimen of Kd70 mg/m2 for relapsed or refractory multiple myeloma (RRMM) is more favourable than the twice-weekly Kd27 mg/m2, as the former is associated with delayed symptom worsening and greater patient-reported convenience and satisfaction, according to a recent study.

The study used data from the open-label, phase III ARROW trial involving 478 adult RRMM patients who were previously treated with 2–3 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent. Of the patients, 240 had been randomized to the once-weekly Kd70 mg/m2 regimen and 238 to the twice-weekly Kd27 mg/m2 regimen.

Researchers compared patient-reported convenience/satisfaction collected at cycle 2, day 1. They also administered European Organization for Research and Treatment of Cancer QOL Questionnaire (QLQ-C30), MM-module (QLQ-MY20) and EuroQoL-5 Dimensions-5 Levels (EQ-5D-5L) questionnaires at baseline and then every other cycle. Patient-reported outcome analyses included 469 patients.

Compared with twice-weekly, the once-weekly regimen conferred greater convenience (odds ratio [OR], 4.98; p<0.001) and satisfaction (OR, 2.41; p=0.059). Fewer patients in the once-weekly arm exhibited a clinically meaningful deterioration in QLQ-C30 Global Health Status/QOL (34.2 percent vs 40.3 percent).

Time from randomization to first deterioration was longer with the once-weekly vs twice-weekly regimen for the following outcomes: QLQ-C30 fatigue (hazard ratio [HR], 0.79; p=0.035), QLQ-MY20 disease symptoms (HR, 0.67; p=0.008), EQ-5D-5L index score (HR, 0.58; p=0.002) and EQ-5D-5L Visual Analog Scale (HR, 0.75; p=0.031).

The present data show that the once-weekly Kd70 mg/m2 carfilzomib dose is superior and convenient, delivering more favourable health-related quality of life in RRMM patients compared with the commonly used Kd27 mg/m2 dose, the researchers said. The once-weekly regimen is therefore positioned to be an important alternative in clinical practice.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 3 days ago
Treatment with hydroxychloroquine appears to significantly reduce viral load in patients with the novel coronavirus disease (COVID-19), with its beneficial effects reinforced by adding azithromycin, results of a recent study have shown.
Dr. Joseph Delano Fule Robles, 04 Sep 2017

A recent genome-wide association study (GWAS) performed by investigators from the Chinese University of Hong Kong (CUHK) has found potential new indications for existing drugs for the treatment of various psychiatric disorders. 

Audrey Abella, 27 Mar 2020
The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.